Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.54 USD
Change Today -0.96 / -3.49%
Volume 43.4K
BPMC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 5:20 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

blueprint medicines corp (BPMC) Snapshot

Open
$27.28
Previous Close
$27.50
Day High
$29.24
Day Low
$26.41
52 Week High
06/18/15 - $37.17
52 Week Low
04/30/15 - $18.00
Market Cap
719.5M
Average Volume 10 Days
82.7K
EPS TTM
--
Shares Outstanding
27.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BLUEPRINT MEDICINES CORP (BPMC)

Related News

No related news articles were found.

blueprint medicines corp (BPMC) Related Businessweek News

No Related Businessweek News Found

blueprint medicines corp (BPMC) Details

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.

60 Employees
Last Reported Date: 06/11/15
Founded in 2008

blueprint medicines corp (BPMC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $311.2K
Co-Founder, Director, Member of Nominating & ...
Total Annual Compensation: --
Chief Business Officer
Total Annual Compensation: $412.5K
Chief Scientific Officer
Total Annual Compensation: $520.0K
Compensation as of Fiscal Year 2014.

blueprint medicines corp (BPMC) Key Developments

Blueprint Medicines Receives FDA Approval for Investigational New Drug Applications

Blueprint Medicines announced that the U.S. Food and Drug Administration accepted the company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 (FGFR4). Aberrant signaling of FGFR4 is a disease driver in up to 30% of HCC patients and may also play a role in a subset of patients with cholangiocarcinoma, a related cancer of the biliary duct.

Blueprint Medicines Corporation Appoints Mark Goldberg to the Board as a Class I Director

On June 25, 2015, the Board of Directors of Blueprint Medicines Corporation, on the recommendation of the nominating and corporate governance committee of the Board, appointed Mark Goldberg, M.D. to the Board as a Class I director of the company, to serve in such capacity until the annual meeting of the Company’s stockholders in 2016 or until his earlier resignation, death or removal. Dr. Goldberg has been a director of ImmunoGen Inc. since 2011, a director of Glycomimetics and Idera Pharmaceuticals since 2014, and a director of aTyr Pharma since earlier in 2015. In connection with his election to the Board, Dr. Goldberg has been appointed to serve as a member of the Compensation Committee of the Board and as a member of the Research and Development Committee of the Board.

Blueprint Medicines Corporation(NasdaqGS:BPMC) added to Russell 2000 Index

Blueprint Medicines Corporation will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BPMC:US $26.54 USD -0.96

BPMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BPMC.
View Industry Companies
 

Industry Analysis

BPMC

Industry Average

Valuation BPMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 70.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 876.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEPRINT MEDICINES CORP, please visit www.blueprintmedicines.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.